此外，泡泡玛特的业务拓展方向还包括实体杂志。4月24日，泡泡玛特推出了实体杂志《play/GROUND》，售价39.9元。 随着泡泡玛特成长为中国头部IP潮玩公司，从业务拓展的角度来看，线上发展影视业务、线下发展主题乐园是较为成熟且具有内在逻辑的发展路径。以电影 业务方面，《哪吒2》票房超过150亿元的巨大盈利想象力，以及电影作为一种强大的内容输出形式，可以通过故事剧情，延伸IP的情感共鸣，也有助于IP吸 引到更广泛的受众群体。线下业务方面，2023年9月26日，首家泡泡玛特主题乐园正式开园，主题乐园通过创新以及适度延展IP形象，拓展营收渠道的同 时，丰富了IP的文化附加值。 随着 LABUBU 在全球范围内爆火，近日泡泡玛特创始人王宁在媒体采访中透露，泡泡玛特已经正式成立电影工作室，将进军电影领域，引起了不小的关 注。 不过，国内影视+衍生品的业务闭环虽然是当下的主流趋势，但多年来仍未发展成熟，泡泡玛特反其道而行从衍生品向电影的发展路，能否助力行业构建起 更加完善、更具竞争力的商业生态体系倒是更值得关注。 进军电影领域的第一部，泡泡玛特即将先行推出的是名为《LABUBU 与朋友们》的动画剧集。 回顾泡泡玛特 ...

来源|贝多财经 6月23日，佰泽医疗集团有限公司（下称"佰泽医疗"，HK:02609）在港交所上市。本次上市，佰泽医疗全球发售1.33亿股，每股发售价为4.22港元，募资总 额约为5.6亿港元，募资净额约4.7亿港元。 上市首日，佰泽医疗的开盘价为5.25港元/股，较IPO发行价上涨24.41%，盘中一度报6.02港元/股。截至收盘，佰泽医疗的股价报收6.00港元/股，较发行价的 涨幅为42.18%，市值约为79亿港元。 特别说明的是，佰泽医疗的公开发售获得25.92倍认购，国际发售获0.98倍认购。同时，此次上市引入1名基石投资者。其中，嘉实国际旗下Harvest Oriental 斥资1900万美元认购该公司发售股份。 据招股书介绍，佰泽医疗是一家主要从事投资及提供医疗相关服务的肿瘤医疗集团。目前，该公司通过6家民营营利性医院的直接股权所有权、2家民营非营 利性医院的管理权，在北京、天津、山西省、安徽省、河南省运营和管理8家医院。 其中，6家民营营利性医院指的是北京京西肿瘤医院、天津石氏医院、天津南开济兴医院、太原和平医院、合肥佰惠长荣医院、武陟济民医院，2家民营非营 利性医院则为黄山首康医院、太原市万柏 ...

2024财年毛利率较去年同期上升1.0个百分点达47.6%，主系部分大宗原材料及包装材料单位耗用成本下 降，抵消因渠道多元化带来的产品结构变动使得集团平均单位售价同比略有降低的影响。受益于毛利率 提升和整体营业费用(分销成本与行政费用合计，后文同)控管得宜，同时因2024财年融资成本的减少及 所得税费用率较2023财年同比降低，2024财年本公司权益持有人应占利润额同比成长8.6%达到43.356亿 人民币，权益持有人应占利润率较去年同期上升1.5个百分点达18.4%。集团将持续深化、强化组织的活 力和能动性，以提升对市场变化的快速反应能力，并进一步扩大市场份额。同时，积极开发新产品，拓 展终端覆盖范围，增强消费者的新鲜感与粘性。尽管当前部分大宗原物料成本有所上涨，但凭借多元化 的原材料使用策略，集团会尽力将成本波动的风险降至最低。 格隆汇6月24日丨中国旺旺(00151.HK)公布，截至2025年3月31日止年度，公司收益为人民币235.11亿 元，同比减少0.3%；毛利为人民币 111.89亿元，同比增长1.8%；营运利润为人民币58.37亿元，同比增 长4.1%。公司权益持有人应占利润为人民币43.36 ...

智通财经6月24日电，中国旺旺全年营收235.1亿元人民币，预估237.2亿元人民币；全年净利润43.4亿元 人民币，预估42亿元人民币。 ...

Core Viewpoint - The ongoing controversy regarding the content of recombinant collagen products from Giant Bio (02367.HK) remains unresolved, with the company not directly addressing anonymous criticisms from testing agencies [1][2]. Group 1: Company Response and Actions - On June 23, Giant Bio acknowledged the limitations of its current quality standards and announced a technical improvement plan in response to market discussions about its recombinant collagen products [2][3]. - The company has conducted a comprehensive self-inspection of its production, testing, and packaging processes, and is validating different testing methods to address recent controversies [3]. - Giant Bio plans to collaborate with research institutions to optimize qualitative and quantitative testing methods for cosmetic recombinant collagen, and will gradually disclose key technical parameters and quality control data [3][4]. Group 2: Industry Standards and Market Impact - Giant Bio has been a pioneer in the recombinant collagen field since applying for a patent in 2001, and it adheres to various industry standards that have been implemented from 2021 to 2025 [3]. - The company's recent statement led to a rebound in its stock price, although it has experienced significant volatility over the past month, dropping from a high of 85.14 HKD on May 20 to 54.6 HKD by June 24 [4]. - The company's market capitalization has decreased by nearly 30 billion HKD from its previous peak, now standing at 584.7 billion HKD [5].

6月18日，全球家庭护理领域头部品牌圣贝拉正式启动IPO招股，作为"全球家庭护理第一股"备受资本市 场关注。此次IPO中，58同城关联方GIMM参投，释放出对高端生活服务赛道长期价值的坚定看好，也 进一步彰显出其围绕生活服务生态展开的持续深耕与战略布局。 伴随中国消费结构不断优化，服务业供需两端持续演进，生活服务已成为连接"美好生活"与产业升级的 重要赛道。58同城正加快打造全场景本地服务生态，依托AI驱动平台能力，精准链接供需两端，推动 服务模式加速进化。 投资优质独角兽品牌，升级本地生活服务价值链 长期以来，58同城对本地生活服务行业的关注并非跟风式参与，而是通过系统性布局，持续拓展服务场 景、推动行业标准化升级，助力服务产业的数字化转型。 人口结构变化、老龄化加速、用工形态多元化趋势明显，服务效率与供给质量优化已成行业共识。数据 显示，2024年家政服务、养老护理、智能健身、母婴护理等领域人才缺口仍超千万，政策端也在不断引 导服务业加快数字化转型。 在此背景下，58同城持续深化"平台+AI"能力建设，强化数字化基础设施，带动生态企业技术升级，未 来将在房产交易智能撮合、招聘AI优化、汽车交易链路智能升级 ...

Core Viewpoint - The report by Liao Asset on Health Road (2587.HK) initiates coverage with a "Buy" rating and a target price of HKD 68.5, indicating a potential upside of 218% from the current price [1] Company Overview - Health Road is a leading full-cycle digital health service platform in China, expanding its enterprise services and digital marketing [1] - The company has established a comprehensive network connecting 2.06 million registered users, 889,000 registered doctors, and 11,762 hospitals, including 1,499 top-tier hospitals [2] - The company’s business model covers the entire healthcare cycle from prevention to management, creating a competitive moat [2] Market Potential - The digital health service market is projected to grow from CNY 113.8 billion in 2024 to CNY 432 billion by 2027, with a compound annual growth rate (CAGR) of 39.10% [1] - By 2030, the market is expected to reach CNY 1 trillion, with a CAGR of 30.30% from 2027 to 2030 [1] Financial Projections - Revenue projections for Health Road from 2025 to 2027 are CNY 2.163 billion, CNY 2.883 billion, and CNY 3.783 billion, with growth rates of 80.10%, 33.29%, and 31.22% respectively [3] - Net profit estimates for the same period are CNY -0.103 billion, CNY 0.135 billion, and CNY 0.332 billion, with growth rates of 61.57%, 231.07%, and 145.93% respectively [3] Competitive Advantages - The company benefits from a stable shareholding structure, with significant stakes held by state-owned and industrial capital, including Baidu at 12.1% and other state-owned entities [2] - The management team possesses strong industry experience and operational capabilities, contributing to improved profitability and decreasing expense ratios [2]

Core Viewpoint - The article discusses how listed companies are increasingly engaging in "hitching a ride" on market trends, particularly through vague statements that connect them to popular brands or concepts, reflecting a broader anxiety within traditional retail and the capital market [1][2][3]. Group 1: Market Behavior - Companies like Wangfujing emphasize their partnerships with popular brands like Pop Mart, despite the minimal financial impact on their overall revenue [1]. - Other companies, such as Yuanlong Yatu and Wanda Film, have also made announcements related to Pop Mart, but these often lack substantial financial data to support claims of significant performance improvement [2][3]. - The phenomenon of companies leveraging market trends often results in superficial connections rather than genuine business integration, driven by a focus on short-term stock price performance [3]. Group 2: Impact on Investors - The practice of "hitching a ride" can mislead retail investors, who may be drawn in by enticing narratives only to find that the anticipated benefits are illusory [4]. - Pop Mart's stock recently experienced a significant drop, losing over 20 billion HKD in market value, highlighting the risks associated with such speculative behaviors [4]. Group 3: Regulatory and Corporate Responsibility - There is a call for improved regulatory frameworks to ensure that companies disclose specific financial metrics related to their market engagements, reducing the potential for misleading statements [5]. - Companies are encouraged to adopt a more responsible approach to market engagement, providing clear and detailed disclosures about their business activities and avoiding ambiguous language [5]. Group 4: Investor Behavior - Investors are advised to focus on fundamental analysis and the core competencies of companies rather than chasing market trends, as this speculative behavior can lead to significant losses [6]. - The article warns against investors who suggest that companies should cater to market trends, as this could lead to conflicts of interest and potential legal issues [6].

经调查，国药控股（天津）东方博康医药有限公司在参加项目编号：2021-WJTYZX-W1102采购活动中，涉嫌存在违规失信行为。 根据军队供应商管理相关规定，自2025年06月20日起暂停其参加武警部队范围物资工程服务采购活动资格。 在暂停期内，法定代表人薛超、自然人控股股东薛超控股或管理的其他企业暂停参加上述范围军队采购活动，授权代表王石磊暂停代理其他供应商参加上述 范围军队采购活动。 6月20日，军队采购网发布关于对国药控股（天津）东方博康医药有限公司暂停处理公告。 同日，军队采购网发布关于对国药控股医疗科技（天津）有限公司暂停处理公告。 经调查，国药控股医疗科技（天津）有限公司在参加项目编号：QX18ZBTJ418、项目编号：2021-WJTYZX-W1102、项目编号：2019-WJTY-A006、项目编 号：2021-WJTYZX-W1087、项目编号：2020-WJTY-A049、项目编号：2019-WJTY-A006采购活动中，涉嫌存在违规失信行为。 根据军队供应商管理相关规定，自2025年06月20日起暂停其参加武警部队范围物资工程服务采购活动资格。 在暂停期内，法定代表人张根起、自然人控股股 ...

Core Insights - Alibaba Cloud's global infrastructure and Tongyi model support Pop Mart's rapid overseas market expansion [1] - Pop Mart's global store system has been migrated to Alibaba Cloud [1] - During the overseas "6.18" period, Pop Mart and AliExpress saw a significant increase in download popularity, ranking high in shopping app downloads across multiple countries and regions [1]